MedTrace Logo

Sargramostim (GM-CSF) + PD-1

NCT04703426 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-05-22

No results posted yet for this study

Summary

This research study is testing the combination of two drugs, sargramostim and pembrolizumab. The study is designed to see if the combination of these study drugs would improve the control of unresectable or metastatic melanoma cancer when compared to use of these drugs alone.

The names of the study drugs involved in this study are:

* Pembrolizumab
* Sargramostim (GM-CSF)

Conditions

Interventions

DRUG

Sargramostim (GM-CSF)

Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.

DRUG

Pembrolizumab (anti-PD-1)

Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Buchbinder, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2024-06-10
Completion
2025-06-09
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04703426 on ClinicalTrials.gov